The use of nanopharmaceuticals in the treatment of neoplasms - a review

Cruz, Cateline; Midões, Cristiana; Nascimento, Luís

Publication

The use of nanopharmaceuticals in the treatment of neoplasms - a review

2025Conference object

datacite.subject.fos	Ciências Médicas
datacite.subject.sdg	03:Saúde de Qualidade
dc.contributor.author	Cruz, Cateline
dc.contributor.author	Midões, Cristiana
dc.contributor.author	Nascimento, Luís
dc.contributor.editor	Arduino
dc.date.accessioned	2025-10-24T13:45:19Z
dc.date.available	2025-10-24T13:45:19Z
dc.date.issued	2025
dc.description.abstract	Cancer is defined by the uncontrolled growth of cells, primarily driven by genetic mutations. Traditional treatments such as surgery, radiotherapy, and chemotherapy frequently fall short due to issues of non-specific targeting and systemic toxicity. However, nanotechnology has decisively emerged as a vital solution to these problems. Nanopharmaceuticals are rigorously formulated, nanoscale pharmaceutical products that have received regulatory approval, while nanoparticle-based therapies represent a broader range of experimental applications. Objectives: This review aims to assertively evaluate the relevance and effectiveness of nanopharmaceuticals in treating neoplasms based on solid scientific evidence. Methods: A systematic review was conducted, leveraging PubMed, MeSH Browser, SciELO, and Web of Science, focusing exclusively on articles published between January 2012 and October 2022 that pertain to nanotherapy for cancer. Studies addressing nanopharmaceuticals in non-cancer conditions or solely concentrating on conventional cancer treatments were rigorously excluded. Results: The analysis of ten selected articles demonstrates that nanoparticle-based therapies provide significant advantages over conventional treatments. These include enhanced intracellular uptake, improved biodistribution, and heightened drug accumulation at tumor sites. Notable nanopharmaceuticals such as SGT-94, BCc1, nab-paclitaxel, and others displayed superior pharmacokinetics and targeted delivery while minimizing systemic toxicity. The majority of studies reported robust safety profiles with manageable side effects and no serious toxicity. Conclusion: Nanomedicine represents a groundbreaking strategy for advancing cancer treatment by enhancing therapeutic precision and reducing adverse side effects. The compelling evidence firmly supports the expanding role of nanopharmaceuticals in oncology. It is imperative that further clinical studies validate their long-term efficacy and safety across larger populations.	por
dc.identifier.citation	Cruz, Cateline; Midões, Cristiana; Nascimento, Luís (2025). The use of nanopharmaceuticals in the treatment of neoplasms - a review. In 13th APLF Annual Conference. Aveiro. ISSN 2042-0986. 16:5, p. 46-47
dc.identifier.doi	10.1177/ 20420986251379201
dc.identifier.issn	2042-0986
dc.identifier.issn	2042-0994
dc.identifier.uri	http://hdl.handle.net/10198/34881
dc.language.iso	eng
dc.peerreviewed	yes
dc.publisher	Sage Publications Ltd
dc.relation.hasversion	journals.sagepub.com/home/taw
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject	Nanoparticles
dc.subject	Antineoplastic
dc.subject	Drug delivery systems
dc.title	The use of nanopharmaceuticals in the treatment of neoplasms - a review	eng
dc.type	conference object
dspace.entity.type	Publication
oaire.citation.endPage	47
oaire.citation.issue	Issue S1
oaire.citation.startPage	46
oaire.citation.title	Therapeutic Advances in Drug Safety
oaire.citation.volume	Volume 16
oaire.version	http://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyName	Nascimento
person.givenName	Luís
person.identifier.ciencia-id	9918-ED25-623E
person.identifier.orcid	0000-0002-1302-2570
relation.isAuthorOfPublication	9e7bebc0-4460-4f4c-b687-10e34c3b36b9
relation.isAuthorOfPublication.latestForDiscovery	9e7bebc0-4460-4f4c-b687-10e34c3b36b9